According
to a new market report published by Transparency Market Research
Pipeline Review of Glioblastoma Treatment Market - Global Industry
Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022, the
global glioblastoma treatment market was valued at USD 0.34 billion
in 2013 and is estimated to reach USD 0.91 billion by 2022 at a CAGR
of 11.4% from 2014 to 2022.Glioblastoma multiforme (GBM), also
categorized as high-grade glioma, is the most aggressive astrocytic
tumor, composed of poorly differentiated neoplastic astrocytes
(subtype of central nervous system cells). The pipeline analysis of
the GBM treatment market has been segmented on the basis of type of
drug and geography. Three drugs that cover the major market of GBM
treatment are bevacizumab (Avastin), temozolomide
(Temodar/Temodal/Temcad), and carmustine (BiCNU). Regions covered in
the geography segment include North America, Europe, Asia Pacific,
and Rest of the World (RoW).
Browse
the full Pipeline Review of Glioblastoma Treatment Market - Global
Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 -
2022 report at
http://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html
The
FDA approved treatments for GBM comprises carmustine, temozolomide,
and bevacozumab. Carmiustine drug is brand named as Gliadel (Arbor
Pharmaceuticals, LLC) which is a surgical implant, while bevacozumab
(Brand name Avastin, product of Genetech/Roche) is targeted for
intravenous therapy and temozolomide (Temodar/Temodal/Temcad and
other brands) is recommended for intravenous or oral chemotherapy.
The factors driving the glioblastoma treatment market include rising
awareness against various types of brain tumors, research and
development in drug delivery technologies and combination of modern
diagnostic techniques. In 2013, temozolomide dominated the global
glioblastoma market due to the therapeutic benefit of
alkylated/methylated DNA, which most often occurs at the N-7 or O-6
positions of guanine residues. In 2012, the drug had lost its
exclusivity and lead to the entry of generic drugs in the market,
thereby, reducing the market share globally.
Geographically,
in 2013 North America dominated the global glioblastoma market owing
to rising incidences of glioblastoma multiforme (GBM) coupled with
increasing number of associations such as American Brain Tumor
Association, National Brain Tumor Society, Brain Tumor Foundation of
Canada and others engaged in raising awareness for GBM in the region.
In addition, majority of the manufacturers developing drugs for the
treatment of glioblastoma are domiciled in the region thereby,
supporting the dominance of the North America market. Asia Pacific is
the most lucrative regional market for glioblastoma due to rising
awareness against GBM which is boosting the diagnostic rate in Asia
Pacific and developing healthcare infrastructure by upgrading the
diagnostic and treatment facilities in Asia Pacific.
Browse
the full Press relaese Report :
Merck
& Co., Inc., F. Hoffmann-Le Roche AG, and Arbor Pharmaceuticals,
LLC are the key players dominated the global GBM treatment market in
2013. The other generic drug manufacturers present in the global
glioblastoma market are Teva Pharmaceutical Industries, Ltd., Amneal
Pharmaceuticals. LLC, Sun Pharmaceutical Industries, Ltd., amongst
others.
The
pipeline review of glioblastoma treatment market has been segmented
as below:
Global
Glioblastoma Treatment Market Revenue and Forecast, by Drugs
Bevacizumab
(Avastin)
Temozolomide
(Temodar and Temodal and Temcad)
Carmustine
(BiCNU)
Global
Glioblastoma Treatment Market Revenue and Forecast, by Geography
North
America
Europe
Asia
Pacific
Rest
of the World
Global
Pipeline Review of Glioblastoma Treatment
Overview
Late
Stage (Phase III)
DCVax
Rindopepimut
(CDX-110)
Others
Early
Stage (Phase I, II and Pre clinical)
ABT-414
MM-398
ARC-100
AV0113
Cotara
Crenolanib
SGT-53
Endostatin
ANG1005
Others
Request
a Brochure of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=4807
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather,
and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Mr.
Nachiket Ghumare
90
State Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com
No comments:
Post a Comment